Market Place
Sourcing Support
Fortress Biotech Reports Q3 2024 Financial Results & Corporate
14 Nov 2024 //
GLOBENEWSWIRE
Fortress Biotech To Participate In October 2024 Conferences
26 Sep 2024 //
GLOBENEWSWIRE
Fortress Biotech Prices $8M Offering
20 Sep 2024 //
GLOBENEWSWIRE
Fortress Biotech To Present At H.C. Wainwright Conference
04 Sep 2024 //
GLOBENEWSWIRE
Fortress Biotech Reports Q2 2024 Results And Corporate Highlights
13 Aug 2024 //
GLOBENEWSWIRE
Fortress Biotech Reduces Debt, Gets 35M Loan From Oaktree
25 Jul 2024 //
GLOBENEWSWIRE
Fortress Biotech Pauses Dividends On 9.375% Series A Preferred Stock
05 Jul 2024 //
GLOBENEWSWIRE
Fortress Biotech To Participate In AGP Healthcare Showcase
16 May 2024 //
GLOBENEWSWIRE
Fortress Biotech Reports Q1 2024 Results, Corporate Highlights
15 May 2024 //
GLOBENEWSWIRE
Fortress Doses First Patient In Triplex Liver Transplant CMV Study
14 May 2024 //
GLOBENEWSWIRE
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
28 Mar 2024 //
GLOBENEWSWIRE
Fortress Biotech to Participate in 36th Annual ROTH Conference
12 Mar 2024 //
GLOBENEWSWIRE
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS
04 Mar 2024 //
GLOBENEWSWIRE
Fortress Biotech Announces Closing of $11 Million Registered Direct Offering
03 Jan 2024 //
GLOBENEWSWIRE
Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering
29 Dec 2023 //
GLOBENEWSWIRE
Cyprium Therapeutics Completes Asset Transfer of CUTX-101 Product Candidate
06 Dec 2023 //
GLOBENEWSWIRE
Fortress Biotech Announces Closing of $10.0 Million Public Offering
14 Nov 2023 //
GLOBENEWSWIRE
Fortress Biotech Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Fortress Biotech Announces Pricing of $10.0 Million Public Offering
10 Nov 2023 //
GLOBENEWSWIRE
Fortress Biotech Announces Launch of Proposed Public Offering
09 Nov 2023 //
GLOBENEWSWIRE
Fortress Subsidiary Helocyte Announces Option Agreement with City of Hope
16 Oct 2023 //
GLOBENEWSWIRE
Fortress Biotech Announces Reverse Stock Split
09 Oct 2023 //
GLOBENEWSWIRE
Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference
05 Oct 2023 //
GLOBENEWSWIRE
Fortress to Present at H.C. Wainwright 25th Annual Global Investment Conference
07 Sep 2023 //
GLOBENEWSWIRE
Fortress Biotech Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023
03 Aug 2023 //
GLOBENEWSWIRE
Urica Announces Topline Data from the Ph1 Trial Evaluating Dotinurad
29 Jun 2023 //
GLOBENEWSWIRE
Fortress Biotech Reports 1Q 2023 FYR Results and Recent Corporate Highlights
15 May 2023 //
GLOBENEWSWIRE
Aevitas Therapeutics Announces Asset Purchase Agreement with 4D Molecular
24 Apr 2023 //
GLOBENEWSWIRE
Fortress Biotech Reports Record 2022 Financial Results
30 Mar 2023 //
GLOBENEWSWIRE
Fortress Biotech to Participate in Two March 2023 Investor Conferences
07 Mar 2023 //
GLOBENEWSWIRE
Avenue secure rare disease med while Allist lands cancer drug
02 Mar 2023 //
FIERCE BIOTECH
Helocyte Announces Data from Stem Cell Transplant Donor Vaccination Trial
16 Feb 2023 //
GLOBENEWSWIRE
Fortress Announces Closing of $13.9M Registered Offering Priced At-the-Market
10 Feb 2023 //
GLOBENEWSWIRE
Fortress Announces Pricing of $13.9M Registered Direct Offering
08 Feb 2023 //
GLOBENEWSWIRE
Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors
19 Dec 2022 //
GLOBENEWSWIRE
Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin
14 Dec 2022 //
GLOBENEWSWIRE
Fortress Biotech Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Lindsay Rosenwald’s Fortress Bio Positioned for Biotech Winter
31 Oct 2022 //
FIERCEBIOTECH
Fortress Biotech Announces Timing of Regular Monthly Dividend for October
05 Oct 2022 //
GLOBENEWSWIRE
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide $20 M
11 Aug 2022 //
GLOBENEWSWIRE
Fortress Biotech Reports Q2 2022 Rusult and Recent Corporate Highlights
11 Aug 2022 //
GLOBENEWSWIRE
Fortress Biotech Appoints David Jin as Chief Financial Officer
22 Jul 2022 //
GLOBENEWSWIRE
Fortress Biotech Announces First Patient Dosed in PI Trial of Dotinurad
31 May 2022 //
GLOBENEWSWIRE
Fortress Biotech to Participate in Two Upcoming May 2022 Investor Conferences
18 May 2022 //
GLOBENEWSWIRE
Fortress Biotech Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Fortress Biotech to Present at 21st Needham Virtual Healthcare Conference
07 Apr 2022 //
GLOBENEWSWIRE
Fortress Biotech Announces Virtual Two-Day R&D Summit
01 Apr 2022 //
GLOBENEWSWIRE
Fortress Biotech Reports Record 2021 Financial Results
28 Mar 2022 //
GLOBENEWSWIRE
Fortress Biotech, Cyprium Tx, Sentynl Tx Announce CUTX-101 Data at 2022 ACMG
21 Mar 2022 //
GLOBENEWSWIRE
Fortress Biotech to Participate in Three March 2022 Investor Conferences
09 Mar 2022 //
GLOBENEWSWIRE
Fortress Biotech Announces Virtual Two-Day Corporate Access Summit
03 Mar 2022 //
GLOBENEWSWIRE
Fortress Biotech to Participate in 2nd Annual Winter Wonderland Conference
07 Feb 2022 //
GLOBENEWSWIRE
Fortress Biotech to Participate in H.C. Wainwright BioConnect Virtual Conference
06 Jan 2022 //
GLOBENEWSWIRE
Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex
16 Dec 2021 //
GLOBENEWSWIRE
Fortress, Cyprium &Sentynl Announce the Initiation of Rolling sNDA for CUTX-101
07 Dec 2021 //
GLOBENEWSWIRE
Fortress shares jump 14%; analysis of data from CUTX-101 Menkes trials
08 Oct 2021 //
SEEKINGALPHA
Fortress Biotech and Cyprium Announce Positive Clinical Data for CUTX-101
08 Oct 2021 //
GLOBENEWSWIRE
Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AZ
06 Oct 2021 //
GLOBENEWSWIRE
